Hanif Ali

Hanif Ali

Auto-generated profile, based on publicly available information

Hanif Ali

Quadrucept Bio Ltd., Kemp House, 152 City Road, London EC1V 2NX, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Science
Verified
Journal Article
Open access
KHKathryn M. Hastie
Kathryn M. Hastie
HLHaoyang Li
Haoyang Li
DBDaniel Bedinger
Daniel Bedinger
SSSharon L. Schendel
Sharon L. Schendel
SDS. Moses Dennison
S. Moses Dennison
ESErica Ollmann Saphire
Erica Ollmann Saphire
Community of antibodies against COVID-19: The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie et al . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV

23 July 2022 in Bioconjugate Chemistry
Verified
Journal Article
Open access
JWJack Wade
Jack Wade
CRCharlotte Rimbault
Charlotte Rimbault
HAHanif Ali
Hanif Ali
LLLine Ledsgaard
Line Ledsgaard
Esperanza Rivera-de-TorreEsperanza Rivera-de-Torre
Esperanza Rivera-de-Torre
Andreas LaustsenAndreas Laustsen
Andreas Laustsen
Recombinantly produced biotherapeutics hold promise for improving the current standard of care for snakebite envenoming over conventional serotherapy. Nanobodies have performed well in the clinic, and in the context of antivenom, they have shown the ability to neutralize long α-neurotoxins in vivo. Here, we showcase a protein engineering approach to increase the valence and hydrodynamic size of neutralizing nanobodies raised against a long α-neurotoxin (α-cobratoxin) from the venom of the monocled cobraNaja kaouthia. Based on the p53 tetramerization domain, a panel of anti-α-cobratoxin nanobody-p53 fusion proteins, termed Quads, were produced with different valences, inclusion or exclusion of Fc regions for endosomal recycling purposes, hydrodynamic sizes, and spatial arrangements, comprising up to 16 binding sites. Measurements of binding affinity and stoichiometry showed that the nanobody binding affinity was retained when incorporated into the Quad scaffold, and all nanobody domains were accessible for toxin binding, subsequently displaying increased blocking potency in vitro compared to the monomeric format. Moreover, functional assessment using automated patch-clamp assays demonstrated that the nanobody and Quads displayed neutralizing effects against long α-neurotoxins from both N. kaouthia and the forest cobra N. melanoleuca. This engineering approach offers a means of altering the valence, endosomal recyclability, and hydrodynamic size of existing nanobody-based therapeutics in a simple plug-and-play fashion and can thus serve as a technology for researchers tailoring therapeutic properties for improved neutralization of soluble targets such as snake toxins.